ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

Children of Male Cancer Survivors Have Highrt Risk of Birth Defects

February 25, 2011

NMP22 Assay More Effective Than Conventional Lab Test

January 27, 2006

Contract Proposal Would Assess Outcomes Other Than Incidence, Response, Mortality

September 18, 1987

ASCO Board Accepts Plan To Establish New Bethesda Headquarters, Hire Chief Officer

April 23, 1993

DCT Board Approves New Screening Program, Natural Product Concpets

March 1, 1985